ab 163 has been researched along with Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belgrad, R; Wampler, GL | 1 |
| Kuperminc, M; Regelson, W; Wampler, GL | 1 |
2 other study(ies) available for ab 163 and Neoplasms
| Article | Year |
|---|---|
A pilot study with ethyl bis (2,2-dimethyl-1-aziridinyl) phosphinate (AB-163) and radiation therapy.
Topics: Adenocarcinoma; Adult; Aged; Aziridines; Azirines; Carcinoma, Squamous Cell; Drug Evaluation; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Pilot Projects; Radiation-Sensitizing Agents; Radiotherapy, High-Energy; Stomach Neoplasms; Uterine Cervical Neoplasms | 1982 |
Phase I study of ethylbis(2,2-dimethyl-1-aziridinyl) phosphinate (AB-163).
Topics: Adult; Aged; Alkylating Agents; Aziridines; Azirines; Drug Evaluation; Female; Humans; Injections, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Vomiting | 1980 |